Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nova Mentis Life Science Corp C.NOVA

Alternate Symbol(s):  NMLSF

Healthcare Biotechnology
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic... see more

Recent & Breaking News (CSE:NOVA)

Nova Mentis Announces Closing of Non-Brokered Financing

PR Newswire March 15, 2022

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

PR Newswire February 16, 2022

/R E P E A T - Nova Mentis and KGK Science Form Tactical Partnership/

PR Newswire January 27, 2022

Nova Mentis and KGK Science Form Tactical Partnership

PR Newswire January 27, 2022

Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

GlobeNewswire January 27, 2022

Nova Mentis Provides Corporate Update - 2022 Planned Catalysts

PR Newswire January 12, 2022

Nova Mentis Welcomes New CFO Rebecca Hudson

PR Newswire December 31, 2021

Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

PR Newswire December 16, 2021

Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference

PR Newswire December 2, 2021

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

PR Newswire November 9, 2021

Nova Mentis to Present at the Wonderland: Miami Psychedelic Conference

PR Newswire November 4, 2021

U.S. FDA Approves Nova Mentis Orphan Drug Application

PR Newswire November 2, 2021

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

PR Newswire October 26, 2021

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

PR Newswire October 19, 2021

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

PR Newswire September 14, 2021

Nova Mentis to Present at the H.C. Wainwright Global Investment Conference

PR Newswire September 9, 2021

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

PR Newswire September 7, 2021

Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency

PR Newswire August 12, 2021

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

PR Newswire July 29, 2021

Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer

PR Newswire July 15, 2021